Inoviq (ASX:IIQ) ROCE %: -50.86% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IIQ Inoviq Ltd ASX:IIQ
27 GF Score
Price A$0.20
GF Value A$0.51
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Inoviq ROCE %?

Inoviq ASX:IIQ 27 ROCE % is -50.86% as of Dec. 2025. GuruFocus rates ASX:IIQ with a GF Score™ of 27/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Inoviq's annualized ROCE % for the quarter that ended in Dec. 2025 was -50.86%.

Inoviq  (ASX:IIQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Inoviq ROCE % Related Terms

Inoviq ROCE % Historical Data

* Premium members only.

The historical data trend for Inoviq's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inoviq ROCE % Chart

Inoviq Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.39 -23.73 -42.78 -39.03 -45.77

Inoviq Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.88 -43.65 -45.35 -43.61 -50.86
ASX:IIQ
27GF Score
Inoviq Ltd ASX:IIQ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inoviq ROCE % Calculation

Inoviq's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-8.493/( ( (21.706 - 1.535) + (18.457 - 1.513) )/ 2 )
=-8.493/( (20.171+16.944)/ 2 )
=-8.493/18.5575
=-45.77 %

Inoviq's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-10.026/( ( (18.457 - 1.513) + (24.516 - 2.036) )/ 2 )
=-10.026/( ( 16.944 + 22.48 )/ 2 )
=-10.026/19.712
=-50.86 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -50.86% mean?
Inoviq (ASX:IIQ) has a ROCE % of -50.86% as of Dec. 2025.
Is Inoviq's ROCE % too high?
Inoviq's current ROCE % is -50.86%. Overall, Inoviq has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's ROCE % compare to TMO and DHR?
Inoviq's ROCE % of -50.86% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Inoviq's current ROCE % is -50.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.20 — trading 60.8% below its estimated fair value. The current ROCE % is -50.86%. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current ROCE % is -50.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inoviq (ASX:IIQ) Overvalued in 2026?

Based on GuruFocus' analysis, Inoviq stock appears to be undervalued. The current stock price of A$0.20 is trading 60.8% below its estimated GF Value™ of A$0.51. GuruFocus considers Inoviq to be Possible Value Trap.

Key valuation signals for ASX:IIQ:

  • ROCE %: -50.86%
  • GF Value™: A$0.51 vs. price of A$0.20 (60.8% below fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inoviq Business Description

Other Exchanges EGQ0:GermanyEGQ0:Germany
Address 23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score

Get the complete analysis for ASX:IIQ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.20
Price
A$0.51
GF Value